These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30676838)

  • 1. Effect of maternal antibody on the infant immune response to inactivated poliovirus vaccines made from Sabin strains.
    Tang R; Chu K; Hu Y; Chen L; Zhang M; Liu S; Ma H; Wang J; Zhu F; Hu Y; Gao Q
    Hum Vaccin Immunother; 2019; 15(5):1160-1166. PubMed ID: 30676838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines.
    Jia S; Tang R; Li G; Hu Y; Liang Q
    BMC Infect Dis; 2020 Aug; 20(1):641. PubMed ID: 32867698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
    Hotta C; Ogawa T; Shirasawa H
    Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement.
    Chen H; Gao Z; Bai S; Liu X; Han S; Xiao Y; Liu F; Yu Y; Sun H; Yang X
    Vaccine; 2021 Apr; 39(17):2467-2474. PubMed ID: 33810904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
    Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
    Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.
    Resik S; Tejeda A; Fonseca M; Alemañi N; Diaz M; Martinez Y; Garcia G; Okayasu H; Burton A; Bakker WA; Verdijk P; Sutter RW
    Vaccine; 2014 Sep; 32(42):5399-404. PubMed ID: 25131734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses.
    Sun M; Li C; Xu W; Liao G; Li R; Zhou J; Li Y; Cai W; Yan D; Che Y; Ying Z; Wang J; Yang H; Ma Y; Ma L; Ji G; Shi L; Jiang S; Li Q
    Clin Infect Dis; 2017 May; 64(10):1317-1325. PubMed ID: 28419204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
    He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
    Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase Ⅱ, randomized, controlled trial to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine.
    Tang R; Li G; Zhang C; Zhi H; Zhu J; Wang J; Liang Q; Hu Y; Li C
    Hum Vaccin Immunother; 2020 Nov; 16(11):2641-2648. PubMed ID: 32347778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.
    Ong-Lim AL; Shukarev G; Trinidad-Aseron M; Caparas-Yu D; Greijer A; Duchene M; Scheper G; van Paassen V; Le Gars M; Cahill CP; Schuitemaker H; Douoguih M; Jacquet JM
    Hum Vaccin Immunother; 2022 Nov; 18(5):2044255. PubMed ID: 35344464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.
    Liao G; Li R; Li C; Sun M; Li Y; Chu J; Jiang S; Li Q
    J Infect Dis; 2012 Jan; 205(2):237-43. PubMed ID: 22158682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms].
    Ye H; Huang T; Ying ZF; Li GL; Che YC; Zhao ZM; Wang JF; Yang XL; Shi L; Jiang RJ; Liu XC; Mo ZJ; Li CG; Yang JS
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jan; 52(1):43-49. PubMed ID: 29334707
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
    Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis.
    Tang G; Yin W; Cao Y; Tan L; Wu S; Cao Y; Fu X; Yan J; Jiang X
    Hum Vaccin Immunother; 2018; 14(11):2636-2643. PubMed ID: 29985751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine.
    Xu J; Liu Y; Qiu W; Li W; Hu X; Li X; Fan Q; Tang W; Wang Y; Wang Q; Yao N
    BMC Infect Dis; 2024 May; 24(1):535. PubMed ID: 38807038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants.
    Gao S; Wei M; Chu K; Li J; Zhu F
    Hum Vaccin Immunother; 2022 Nov; 18(5):2050106. PubMed ID: 35394898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
    Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
    Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
    Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.
    Liao G; Li R; Li C; Sun M; Jiang S; Li Y; Mo Z; Xia J; Xie Z; Che Y; Yang J; Yin Z; Wang J; Chu J; Cai W; Zhou J; Wang J; Li Q
    J Infect Dis; 2016 Dec; 214(11):1728-1734. PubMed ID: 27658691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.